CardioComm Solutions Inc (EKG)

CardioComm Solutions and Predictiv AI Enter into Strategic AI CollaborationJune 8, 2026 9:11 AM
NewsfileToronto, Ontario--(Newsfile Corp. - June 8, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a provider of consumer heart monitoring, remote patient monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has entered into a strategic collaboration, joint development and intellectual property agreement with Predictiv AI Inc. ("Predictiv AI") of North York, Ontario.The agreement establishes a framework under which the companies may identify, assess and, where mutually approved, pursue specific projects involving healthcare software, medical software, artificial intelligence, automated analytics, remote patient monitoring, clinical decision support, biosignal interpretation, predictive analytics, workflow optimization and software as a medical device applications.Under the collaboration framework, Predictiv AI is expected to contribute capabilities in artificial intelligence, telemetry aggregation, data intelligence and predictive analytics, while CardioComm is expected to contribute its proprietary medical software, ECG management technologies, regulatory experience, quality system expertise and commercialization experience applicable to medical devices and medical software.The agreement is structured to preserve each company's existing intellectual property, prior art, confidential information and proprietary technologies, while setting out procedures for the ownership, protection and use of any intellectual property that may be jointly developed under approved projects. Specific projects, deliverables, budgets, timelines, regulatory activities and commercialization commitments will require separately approved written project schedules or definitive agreements.For any project that may involve regulated medical software, software as a medical device, clinical workflows or medical device-related deliverables, CardioComm will retain final decision-making authority over quality, regulatory, validation, cybersecurity, information security and release-related matters, including compliance with CardioComm's ISO 13485 quality management system and ISO 27001 information security requirements.The areas of potential collaboration include AI-enabled remote patient monitoring, automated ECG and biosignal interpretation, multi-parameter data fusion, clinical workflow automation, event prioritization, triage support, predictive analytics and regulated software applications. The parties also expect to evaluate opportunities intended to support healthcare providers in reviewing medical data more efficiently and identifying clinically relevant events.In connection with the collaboration agreement, the Company notes that its Chief Executive Officer, Mr. Etienne Grima, also serves as a director of Predictiv AI. Mr. Grima disclosed his interest in the matter and did not participate in the Board's consideration or approval of the agreement. Any future project-specific commercial terms are expected to be addressed separately through written project schedules or definitive agreements, as applicable.To learn more about CardioComm's products and for further updates please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com. About CardioComm Solutions, Inc.CardioComm Solutions, Inc. is a healthcare technology company focused on the development of medical software, remote patient monitoring solutions, and data management platforms for the collection, analysis, and reporting of cardiac and related physiological data. The Company's technologies support patients, physicians, and healthcare organizations through clinically relevant, connected digital health solutions. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada). About Predictiv AI Inc. Predictiv AI Inc. is a Canadian artificial intelligence company focused on developing vertical AI applications for defined industries. The Company's products address fleet operations and communications, including fleet management software, AI-based agents for voice, chat, and SMS, and tools designed to support structured operational workflows. For more information, please visit www.predictiv.aiFOR FURTHER INFORMATION PLEASE CONTACT:Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.comForward-looking statements This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300503 Original: CardioComm Solutions and Predictiv AI Enter into Strategic AI Collaboration

CardioComm Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933May 8, 2026 4:01 PM
NewsfileToronto, Ontario--(Newsfile Corp. - May 8, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leader in consumer heart monitoring, remote patient monitoring, and medical electrocardiogram ("ECG") software solutions, announces that it has elected to rely on Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-933 allows eligible venture issuers listed on the TSX Venture Exchange (the "TSXV") to voluntarily move from a quarterly to a semi-annual financial reporting framework. The Company's fiscal year ends on December 31. Under the SAR pilot program:Interim Period: The Company will be exempt from filing an interim financial report and related Management's Discussion & Analysis for the first quarter (Q1) ended March 31, 2026 and the third quarter (Q3) ending September 30, 2026; andOngoing Reporting: CardioComm will continue to file audited annual financial statements (due within 120 days of December 31, 2026) and six-month interim financial reports (due within 60 days of June 30, 2026).The Company confirms it meets the SAR pilot program's eligibility criteria, which include being a venture issuer with annual revenues of less than $10 million as shown on its most recently filed audited annual financial statements, having been a reporting issuer in at least one jurisdiction of Canada for 12 months or more, and having filed all required periodic and timely disclosure documents under applicable Canadian securities legislation.This news release is being filed pursuant to Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers. About CardioComm Solutions, Inc.CardioComm Solutions, Inc. is a healthcare technology company focused on the development of medical software, remote patient monitoring solutions, and data management platforms for the collection, analysis, and reporting of cardiac and related physiological data. The Company's technologies support patients, physicians, and healthcare organizations through clinically relevant, connected digital health solutions. CardioComm has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada). FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.comForward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm and certain of the plans and objectives of CardioComm with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information. In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296712 Original: CardioComm Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933

EKG just starting to roll ,I see $1.00 coming shortly

A couple news releases this last week, anyone left on this board or did everyone decide they have waited long enough, I believe this stock is about to take a fast turn to the upside.

First quarter financials will be out June 30,2020

No, But there is possibly a light at the other end of tunnel, reading Stockhouse this morning and one post said financials for first quarter are due out this Friday, and the first sales of the so called new hardware will be included

is it better or no?

Financials are now out for the 4th 1/4 of 2019

EKG you can buy on shopify.com https://theheartcheck.myshopify.com/products/heartcheck-cardibeat-bluetooth

EKG(TSXV) or (OTC: EKGGF)~ CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at

https://www.theheartcheck.com

https://www.cardiocommsolutions.com

very undervalued

I am also..

Apple has and other smartphone companies need EKG kind of application. EKG is the only cheapest stock with a FDA approved products and software... this company is way undervalued imho.. I was remember how it was running from 2 cents to 66 cents when FDA approved their products.. .
EKG's product also got approval from Health Canada, Europe CE and Japan.. So if any smart phone takeover them.. they use that application for all over the world without any problem imho.
Have you ever contacted to CEO? looks like that ceo doesn't know how to marketed this product..

CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at

https://www.cardiocommsolutions.com

and

https://www.theheartcheck.com

If that happens then we could easily hit .50 to .75 in my opinion

how about takeover?? solid product it is possible, especially smart cellphone companies need that applicaiton.

Depending on 2 sets of financials that are suppose to be coming out 1 next week and the other around June 19. I'm hoping that the 1st quarter financials which are due around the 19th will show a noticeable increase in revenue. If so we will very likely see this stock run up a little maybe even a lot.
lol

EKGGF for traders in USA! https://www.otcmarkets.com/stock/EKGGF/disclosure

I like this company amazing device and application but share price is not reflecting this great product ..

CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at

https://www.cardiocommsolutions.com

and

https://www.theheartcheck.com

Something up with EKG, keep an eye on it .

Wowsers not a post on here and yet FDA approval news out. Thought this would be hoping.

time to load this one

wow big volume today 33% up >>>

Looking into this one

EKG.V big news out!!: CardioComm Solutions Announces International GEMS Home and SMART Monitoring Service Licensing Agreement with Beijing Choice Electronic Technology of China

CardioComm Solutions Announces International GEMS Home and SMART Monitoring Service Licensing Agreement with Beijing Choice Electronic Technology of China

$EKG http://finance.yahoo.com/news/cardiocomm-solutions-confirms-australian-regulatory-170000421.html

not yet insiders selling shares. the biggest holder sold lots of shares recently. when he done maybe.. wait the dip..

you think the bounce platform settin up on this one??

we should be seeing some numbers from the WAISCO deal

Any update from the WAISCO Distribution agreement..? http://www.wikinvest.com/stock/Cardiocomm_Solutions_Inc_(EKG)/News/4033891

"With completion of two American distributor agreements, CardioComm Solutions will continue to work in closing additional distribution and partnership agreements for our family of HeartCheck and Global ECG Management (GEMSTM) solutions, each with a different focus within multiple global geographic and demographic markets".

:))

EKG.V news out: CardioComm Solutions Engages National Distributor of the HeartCheckTM PEN ECG Device to the Seniors and Aging Boomer Market in the USA.
CardioComm Solutions, Inc. EKG
3/6/2013 12:25:00 PM
CardioComm Solutions Engages National Distributor of the HeartCheckTM PEN ECG Device to the Seniors and Aging Boomer Market in the USA.

(via Thenewswire.ca)

March launch targets in excess of 2.5 million American seniors for sales of the only FDA OTC cleared ECG based heart rhythm monitoring solution.

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced a distribution agreement with firstSTREET for Boomers and Beyond Inc., based out of Virginia ("Vendor"), a specialist in the design and marketing of innovative specialty products for seniors. FirstSTREET will be selling the HeartCheck PEN into the U.S. market commencing immediately.

The agreement designates firstSTREET as an authorized re-seller of the HeartCheck PEN. CardioComm Solutions anticipates revenue from sales of devices as well as generation of revenue from ECG triage and interpretation services through use of the Company's SMART Monitoring ECG service.

As a direct marketing company, firstSTREET advertisements will reach the senior customer through the Internet, monthly catalogs and national periodical-based publications. Their website lists such publications as AARP's Bulletin and Magazine, Parade and USA Weekend. Their internet site has been recognized as one of the Top 500 Internet Web sites by Internet Retailer magazine, placing them in the company of: Amazon, BestBuy, Dell, eBay, LandsEnd, and DrugStore.com. Further they are the only Top 500 internet site that focuses exclusively on the senior demographic, which represents the fastest growing on-line user group.

"The launch of our second American distribution agreement follows discussions initiated in November 2012", said Etienne Grima, Chief Executive Officer for CardioComm Solutions. "This one distribution agreement is a significant opportunity for CardioComm Solutions to introduce the HeartCheck PEN specifically into the seniors market in the United States. Given the network of channel partners and firstSTREET's own household file of 2.5 million customers with an average of 65 years of age, this launch meets our objective to access elderly consumers interested in the preservation of their health as well as those at risk for developing arrhythmia based cardiac disease due to underlying conditions such as hypertension, diabetes, older age, familial histories and taking high risk medications".

TO VIEW IMAGE COPY AND PASTE URL BELOW TO NEW BROWSER WINDOW

http://thenewswire.ca/client_files/2013-03-06-0.pdf

Consumers purchasing the HeartCheck PEN ECG will have access to CardioComm Solutions' SMART Monitoring ECG service, a first free ECG interpretation by the CardioComm Solutions ECG service and the free GEMS Home software. After the free interpretation, the HeartCheck PEN can be enabled to display the ECG waveform at no additional cost (see inserted image).

"firstSTREET has placed the HeartCheck PEN on the front cover of their spring catalogue as a feature product anticipated to be sent to 350,000 of their opt in clients as of March 4, 2013, as well as placing it on the new arrivals featured products section of their website at www.firststreetonline.com", added Mr. Simi Grosman, member of the Company's Board of Directors. "With completion of two American distributor agreements, CardioComm Solutions will continue to work in closing additional distribution and partnership agreements for our family of HeartCheck and Global ECG Management (GEMSTM) solutions, each with a different focus within multiple global geographic and demographic markets".

About CardioComm Solutions

CardioComm Solution's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer

1-877-977-9425

egrima@cardiocommsolutions.com

www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Copyright (c) 2013 Thenewswire.ca - All rights reserved.

TheNewsWire
March 6, 2013 - 12:25 PM EST

EKG.V Target Price: $14.11, Upside Potential: 10,754%

FDA Approves the First Ever Over-the-Counter Heart Monitoring Solution
EKG.V CURRENT PRICE: $0.13
EKG.V TARGET PRICE: $14.11
UPSIDE POTENTIAL: 10,754%
SHARES OUTSTANDING: 77,436,440

January 22, 2012 - Toronto, Ontario - CardioComm Solutions, Inc. (TSXV:EKG) rose 200% on Friday after the FDA approved their consumer-based, hand-held heart rhythm monitor known as the HeartCheck™ Pen Handheld ECG. This is the first ever heart monitor that has been approved for over-the-counter sales and marketing purposes.

See the full release here

The company has 77.4M shares outstanding and 19 million warrants to be exercised at 10 cents. Assuming all the warrants will get exercised that would increase the share total to 96.4M with a $1.9M cash infusion to the company. With a share price of 13 cents that would assume a mere $12.5 market cap or $10.6M of enterprise value.

27.1M people in the United States alone suffer from heart disease. Assuming only 5% of these people buy the HeartCheck™ Pen Handheld ECG in the first year that would be 1.36M devices sold. If each device were to sell for $100, that would imply $136M of revenue in the first year alone.

A 50% margin would be conservative for a company with a patent on the first ever Over-the-Counter heart monitor, essentially becoming a monopoly in this very important niche. A 50% margin on $136M of revenue is $68M in net profit. Applying a very conservative 20 Price to Earnings multiple to this figure would imply a $1,360M enterprise value.

Dividing $1,360M in enterprise value by 96.4M shares outstanding would imply a price per share of $14.11, assuming that only 5% of Americans diagnosed with heart disease purchase this extremely useful tool in the first year it is on the market. This assumes no other sales from Canada or any other country and given America's aging population and high rates of obesity, the HeartCheck™ Pen sales are very likely to increase each year. CardioComm Solutions is vastly undervalued at its current share price and has great potential to be the biggest percent gainer on the TSX Venture for 2012.


http://tsxnews.blogspot.com/2012/01/fda-approves-first-ever-over-counter.html

EKG.V 2 million shares buyback from the open market
http://www.cardiocomm.com/news/pdf/TSX_News_report.pdf

Recently, EKG.V biggest shareholder chairman of the company Prof. LANGER's company (so far holds 41 million EKG.V shares) decied to buy from the opne market 2% of shares.

HERE IS THE NEWS LINK

http://www.cardiocomm.com/press/2013/Jan%2015%202013.pdf

2) HERE IS MORE INFORMATION ABOUT PROF. LANGER

http://www.cardiocomm.com/bios/anatoly_langer.html

3) HERE IS THE LINK HE PURCAHSED SHARES FROM THE OPEN MARKET

http://canadianinsider.com/node/7?menu_tickersearch=EKG+|+CardioComm+Solutions
Read more at http://www.stockhouse.com/bullboards/messagedetail.aspx?s=EKG&t=LIST&m=32277340&l=0&pd=0&r=0&msg=3#IGLHFhiSqYOb9gSE.99

EKG.V so far volume 30 times bigger than average daily volume

In below 20

EKG.V this time we will see 1 DOLLAR PLUS LOAD AND LOCK. THIS IS VERY THIN.. DO NOT SELL HARD TO GET AT THESE PRICE AGAIN.

Yes Sir .. Looking good

their float 35 million insiders loading big they can go up multi-dollars LOAD AS MUCH AS YOU CAN

they can sell all over the world, each one 120 dollars. if they sell this year 1 million it will generate 120 million dollars revenue..

Thanks for the heads up. Re-bought late yesterday on the news , which is significant. Long-term Chart looks great for a rebound too.

It looks as if additional distribution agreements are coming for the Heart Check pen.. Also Anatoly Langer holds 41 million shares of this company's common.. Time to re enter imo

Here is a link to Stockhouse Bull Board message for Cardiocomm..

http://www.stockhouse.com/bullboards/messagedetailthread.aspx?p=0&m=32269227&l=0&r=0&s=EKG&t=LIST

EKG.V 80% up

EKG.V exploding today big news out

EKG.v EXPLODING

Blue.. What do you think of this one about now ??

looks to be getting near load time on EKGGF

Should of said "sell and go away in MAY stock" in my last post

This stock has been slipping of late as management have been working overtime to get things lined up,private placements , contracts,and promotion, the fruits of thier hard work should start showing up in the stock price any day now,yesterday the stock started moving back up again, unlike mining stocks this is not a sell and go away stock like many mining companies as this could move up very quickly with one news release on a contract or maybe even a buyout.....